Anti-IL13 Recombinant Immunotoxin Cintredekin Besudotox (IL13-PE38QQR)

Target

IL13

IT Type

Ligand-based IT

Description

Cintredekin besudotox has been developed as a specific tumor targeting agent that can be directly applied to brain tissue at risk of residual infiltrating glioblastoma (GBM) after tumor resection through positive pressure convection enhanced delivery (CED). Cintredekin besudotox is made of human protein Interleukin 13 (IL13) linked to the bacterial toxin Pseudomonas exotoxin (PE). IL13 partially binds to receptors on the tumor.

Indication

Brain cancer

Classification

Immuntoxin; biobetter

Construction

IL13-PE38QQR

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.

Official Name

IL13

Full Name

Interleukin 13

Background

This gene encodes an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines. This cytokine is found to be critical to the pathogenesis of allergen-induced asthma but operates through mechanisms independent of IgE and eosinophils. This gene, IL3, IL5, IL4, and CSF2 form a cytokine gene cluster on chromosome 5q, with this gene particularly close to IL4. [provided by RefSeq, Jul 2008]

Alternative Names

Interleukin 13

Gene ID

Entrez Gene: 3596

UniProt ID

UniProtKB: P35225

Biologic Classification

Protein Based Therapies
Monoclonal antibody (mAb)

Species Reactivity

Human

Antibody Indication

Brain cancer

LIgand

IL13 receptor

Toxic Moiety

PE38QQR

Organism

Pseudomonas aeruginosa

Family

Pseudomonas exotoxin A

Molecular Mass

38 kDa

Toxic MOA

PE38 is a 38 kDa truncated form of Pseudomonas exotoxin (PE) containing amino acids 253–364 and 381–613. Pseudomonas exotoxin (or exotoxin A) is an exotoxin produced by Pseudomonas aeruginosa. Vibrio cholerae produces a similar protein called Cholix toxin (Q5EK40). It inhibits elongation factor 2. This is achieved by ADP ribosylation of EF2 using NAD +. This then causes the extension of the polypeptide to stop. This mechanism is similar to diphtheria toxin.

Recombinant chimeric protein with strong anti-tumor activity. Cintredekin besudotox consists of the pleiotropic immunomodulatory cytokine interleukin 13 (IL13), which is linked to the mutant form of Pseudomonas exotoxin A. The drug targets and kills tumor cells that express IL13 receptor (IL13R). IL13 is partially attached to IL13R on the tumor cell membrane, promoting the entry of exotoxin. Exotoxin induces caspase-mediated apoptosis of tumor cells in part through mechanisms involving mitochondrial damage. It also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor 2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis.

Brain cancer

Anti-IL13 Recombinant Immunotoxin Cintredekin Besudotox (IL13-PE38QQR) (CAT#: BioBet-IT001Z) Datasheet

Biobetters

Target

Target Moiety

Toxin Moiety

Mechanism of Action

Indication

ONLINE INQUIRY